Mesoblast Ltd. appointed James M O’Brien as its US-based Chief Financial Officer as part of its transition to a fully integrated commercial organization. O’Brien’s previous CFO roles include Cognition Therapeutics, Inc. and Faron Pharmaceuticals, Ltd. The company reported a revenue of $20.6 million from cell therapy products for the first quarter, a significant increase from the previous quarter. On the NASDAQ, MESO closed at $14.77 on Friday, down 1.01%, and was trading at $14.48 in after-hours trading.

Read more at Nasdaq MarketSite.: Mesoblast Appoints James M O’Brien New CFO